FDA warns J & J on insulin pumps

Share this article:

Johnson & Johnson could face penalties for not reporting incidents where insulin pumps have failed, the Food and Drug Administration has warned.

In a Dec. 27 letter to the company's Animas Corp. unit, the FDA says the company should have reported incidents where the device failure may have caused injury, including diabetic ketoacidosis. It also said Animas failed to create a system for making adequate medical device reports.

The letter, which was made public last week, followed a site visit in 2011. It warns “failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.”

Diabetes is among the top ten leading causes of death in the U.S. Insulin pumps deliver rapid- or short-acting insulin throughout the day via a catheter rather than require a person or caregiver to do periodic injections.



Share this article:

More in News

House bill would define, promote coordinated long-term care services

A bill introduced in the House of Representatives would target improved care coordination for seniors, also adding it under the Older Americans Act.

Skilled nursing facility trends contribute to improved Medicare outlook, Congressional report says

The Medicare trust fund is on track to remain solvent until 2030, trustees of the program stated in a Congressional report released Monday. This improved outlook is due in part to revised expectations about the case mix in skilled nursing facilities.

Seize the day: Tech Awards deadline is tomorrow

Seize the day: Tech Awards deadline is tomorrow

The final countdown has begun: Long-term care providers have less than 48 hours to enter the third annual McKnight's Excellence in Technology Awards. Submissions will be accepted through July 30.